Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S.
N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.
AL Amyloidosis: Current Treatment and Outcomes.
Locke M, Nieto M.
Adv Hematol. 2025 Mar 3;2025:7280805. doi: 10.1155/ah/7280805. eCollection 2025.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R.
Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.
Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini-Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hebraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Cherel B, Frenzel L, Vekemans MC, Bigot N, Avet-Loiseau H, Corre J, Moreau P.
Blood. 2025 Jul 3;146(1):52-61. doi: 10.1182/blood.2024026230.
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report.
Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kröger N, Thiele J, Barbui T, Barosi G.
Blood. 2013 Aug 22;122(8):1395-8. doi: 10.1182/blood-2013-03-488098. Epub 2013 Jul 9.
Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia.
Hanna J, Zabor EC, Albliwi M, El-Asmar J, Nurse DP, Bawwab A, Abuamsha H, Abu-Farsakh Y, Batah H, Rauf A, Nakitandwe J, Bosler DS, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Sobecks RM, Advani AS, Carraway HE, Astbury C, Mustafa Ali MK.
Am J Hematol. 2025 Sep;100(9):1577-1589. doi: 10.1002/ajh.70000. Epub 2025 Jul 11.
Construction and validation of joint dose-response curves for chromosome aberrations and interphase lymphocyte survival for cytogenetic biodosimetry of partial exposure.
Vinnikov V, Kochanová D, Vigašová K, Gulati S, Košík P, Durdík M, Jakl L, Zastko L, Kontrišová K, Martinka K, Marková E, Belyaev I.
Int J Radiat Biol. 2025 Jul 17:1-14. doi: 10.1080/09553002.2025.2531905. Online ahead of print.
[Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment].
Fujii S, Miura I, Tanaka H.
Rinsho Ketsueki. 2015 Jun;56(6):681-6. doi: 10.11406/rinketsu.56.681.
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine.
Li X, Chang C, He Q, Xu F, Zhang Q, Wu L, Su J, Zhang X, Zhou L, Wu D, Song L, Zhang Z.
Leuk Res. 2013 Nov;37(11):1516-21. doi: 10.1016/j.leukres.2013.09.006. Epub 2013 Sep 18.
[Acute myeloid leukemia].
Ohtake S.
Gan To Kagaku Ryoho. 2007 Dec;34(13):2175-9.
